Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib
NCT ID: NCT03727477
Last Updated: 2023-05-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
291 participants
OBSERVATIONAL
2019-02-01
2020-10-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
NCT04362072
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
NCT04042558
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
NCT06378892
Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)
NCT00418704
Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost
NCT06627738
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who received at least one week of treatment with lorlatinib as part of the French Expanded Access Program (ATU program); ATU was granted due to their inability to meet eligibility criteria for on-going recruiting trials, inability to participate in other clinical trials (e.g., poor performance status, lack of geographic proximity), or because other medical interventions are not considered appropriate or acceptable.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Intergroupe Francophone de Cancerologie Thoracique
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicolas Girard, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Institut Curie Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aix-en-Provence - CH
Aix-en-Provence, , France
Angers - CHU
Angers, , France
Annemasse - CH
Annemasse, , France
Avignon - CH
Avignon, , France
Bordeaux - Polyclinique
Bordeaux, , France
Brest - Morvan CHU
Brest, , France
Cahors - CH
Cahors, , France
Chartres-CH
Chartres, , France
Clermont-Ferrand - CHU
Clermont-Ferrand, , France
Colmar - CH
Colmar, , France
Créteil - CHI
Créteil, , France
La Roche-Sur-Yon - CH
La Roche-sur-Yon, , France
Libourne - CH
Libourne, , France
Lorient - CHBS
Lorient, , France
Lyon - CRLCC
Lyon, , France
Marseille - CRLCC
Marseille, , France
Montpellier - ICM
Montpellier, , France
Mulhouse - GHRMSA
Mulhouse, , France
Paris - Curie
Paris, , France
Paris - Saint-Louis
Paris, , France
Paris - Tenon
Paris, , France
Lyon - URCOT
Pierre-Bénite, , France
Reims - CHU
Reims, , France
Saint-Etienne - CHU
Saint-Etienne, , France
Saint-Nazaire - Clinique Mutualiste de l'Estuaire
Saint-Nazaire, , France
Toulouse - CHU
Toulouse, , France
Tours - CHU
Tours, , France
Valenciennes - Clinique
Valenciennes, , France
Vandoeuvre-lès-Nancy - CRLCC
Vandœuvre-lès-Nancy, , France
Villejuif - Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Girard N, Galland-Girodet S, Avrillon V, Besse B, Duruisseaux M, Cadranel J, Otto J, Prevost A, Roch B, Bennouna J, Bouledrak K, Coudurier M, Egenod T, Lamy R, Ricordel C, Moro-Sibilot D, Odier L, Tillon-Strozyk J, Zalcman G, Missy P, Westeel V, Baldacci S. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study. ESMO Open. 2022 Apr;7(2):100418. doi: 10.1016/j.esmoop.2022.100418. Epub 2022 Feb 26.
Baldacci S, Besse B, Avrillon V, Mennecier B, Mazieres J, Dubray-Longeras P, Cortot AB, Descourt R, Doubre H, Quantin X, Duruisseaux M, Monnet I, Moro-Sibilot D, Cadranel J, Clement-Duchene C, Cousin S, Ricordel C, Merle P, Otto J, Schneider S, Langlais A, Morin F, Westeel V, Girard N. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. Eur J Cancer. 2022 May;166:51-59. doi: 10.1016/j.ejca.2022.01.018. Epub 2022 Mar 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IFCT-1803
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.